Good news for patient in Canada. Announced on 19-Mar, a new medicine  called Cymbalta® (duloxetine HCl)  has been approved is for the symptomatic relief of anxiety causing clinically significant distress in patients with Generalized Anxiety Disorder (GAD)

The approval is based on the studies of 2,700 non-depressed adults. The pool data shows improved core anxiety symptoms by 45% and significantly less replased of 13.7% in a 26 week study. Cool results as compared to those who took placebo.

What are the common side effects for these subjects? Nausea, dizziness, dry mouth, fatigue, constipation, somnolence, and increased sweating.

This medicine is produced by Eli Lilly Canada Inc. and Boehringer Ingelheim (Canada) Ltd.

About Generalized Anxiety Disorder
The one-year prevalence of GAD in the general population is about 1 per cent to 3 per cent, and the lifetime prevalence is about 6 per cent.   While anxiety is a symptom of many mental health disorders, including depression, GAD is more than simple anxiety. The essential feature of the disorder is excessive anxiety and worry about a number of events and activities (such as work or school performance), occurring for a majority of days for at least six months. 

About Duloxetine
Cymbalta (duloxteine HCl) is a potent and balanced serotonin and norepinephrine reuptake inhibitor (SNRI), which targets two chemical messengers in the brain believed to play a role in mood and sensitivity to pain – serotonin and norepinephrine. While the mechanism of action of duloxetine in humans is not fully known, scientists believe its effect on pain perception and mood is due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Via http://www.medadnews.com/News/index.cfm?articleid=613269



Written by Andrew - Visit my post on
Panic Away Ebook Review by Joe Barry or
Cure Anxiety and Panic Attacks Ebook Review by Peter Nagy

Incoming search terms:

  • generalized anxiety disorder curable
  • is anxiety is cruable with medicine